Tuesday, January 04, 2022
Baudax Bio, Inc. (BXRX)
Taking the Pain Away; Initiating Coverage with an Outperform Rating
Baudax Bio is a biopharmaceutical company focused on developing therapies for post-operative pain, peri-operative pain, and anesthesia. The company currently has one approved therapy in ANJESO for post-operative pain. Proprietary ANJESO (meloxicam) injection is the first and only once-daily IV analgesic. The company also has a pipeline of early-stage candidates with two novel neuromuscular blocking agents (NMBAs), a proprietary related reversal agent to their NMBAs, and Dex-IN, an intranasal formulation of dexmedetomidine (Dex) that has sedative, analgesic, and anti-anxiety properties.
Gregory Aurand, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Baudax Bio Is Developing Non-Addictive Therapies For Pain Management. The opioid crisis continues and Baudax has large market opportunity proprietary treatments for post-operative pain, peri-operative pain, and anesthesia, with one non-addicting product FDA approved and commercialized for post-operative pain.
ANJESO Is the First and Only Once-Daily IV Analgesic. ANJESO is approved for management of moderate to severe pain, alone or in combination with other non-NSAID analgesics for up to 24 hours of pain relief. The product is a once-daily NSAID IV injection with preferential Cox-2 activity …
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
